Editor
David Chen
Editor · drug development, then telehealth
This index is edited by someone who has worked on both sides of the market it measures — years inside drug development, and a period previously spent helping run a telehealth practice that prescribed GLP-1 medications. That is why the site is built around what a seller actually bills rather than what it advertises: from the inside, the gap between those two numbers is not a mystery.
The editor is not a licensed clinician, and this site gives no medical advice. Every clinical statement here is sourced to FDA prescribing information or to a named paper whose PMID has been verified against the record. Where the label is silent, the page says the label is silent rather than filling the gap.
The same editor writes Compounded Tirzepatide and Compounded Semaglutide. They are two sites because they cover two different drugs, and each one is priced on its own: every figure is read on that seller's own site for that drug, and a price found on one site is never copied across to the other.
Think of the site as a directory. It lists every US seller we can find, gives each one's real monthly price, and sums up what that seller's own site says about its plans, billing and where it ships. Each price is read on the seller's own site, stored with the date it was checked and a link to where it was read, then restated over a 30.4375-day calendar month from the amount actually charged. The method is at /how-we-verify and the whole dataset is downloadable, so no figure has to be taken on trust.
What this site covers
383 US sellers of compounded tirzepatide, each price read on the seller’s own checkout and restated as a real calendar month. The method is at how we verify, the corrections log at corrections, and the commercial relationships at disclosure.
Nothing on this site is medical advice, and the editor is not a licensed clinician. Clinical statements are sourced to the approved product’s label or to a named paper with its PMID verified against the record — see the medical disclaimer and the editorial policy.